GlassScriptPhysician profile
Dinesh Keerty
NPI 1164785291
$6,843.48
in general payments reported to CMS, 2019-2025
51 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $643 · 2023: $1,631 · 2024: $2,202 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,327 · Education: $674 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,327.05 |
| Education | $674.39 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $738.28 | 2022-2025 | Darzalex, Rybrevant, Imbruvica |
| Novartis Pharmaceuticals Corporation | $657.46 | 2023-2025 | |
| Daiichi Sankyo INC. | $529.09 | 2022-2025 | Enhertu, Injectafer |
| Abbvie INC. | $403.24 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $399.80 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $389.22 | 2022-2025 | Lynparza, Imfinzi, Calquence |
| Genentech USA, INC. | $282.68 | 2022-2025 | Tecentriq, Polivy, Phesgo |
| Aveo Pharmaceuticals, INC. | $265.23 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $252.47 | 2022-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $223.16 | 2023-2025 | Libtayo, Lynozyfic |
| Eisai INC. | $213.91 | 2022-2025 | |
| Glaxosmithkline, LLC. | $175.28 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Pfizer INC. | $155.09 | 2023-2025 | |
| Genmab U.S., INC. | $131.42 | 2023-2025 | Tivdak, Epkinly |
| Celgene Corporation | $118.58 | 2022-2025 | Reblozyl |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $117.82 | 2022-2025 | Adcetris |
| Kite Pharma, INC. | $117.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.56 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $112.50 | 2022 | |
| Astellas Pharma US INC | $99.06 | 2023-2025 | Padcev, Xospata, Xtandi |
| Incyte Corporation | $95.75 | 2024-2025 | Zynyz, Monjuvi, Jakafi |
| Adaptive Biotechnologies Corporation | $89.54 | 2023 | Clonoseq |
| Gilead Sciences, INC. | $86.31 | 2025 | Trodelvy |
| Puma Biotechnology, INC. | $84.02 | 2024 | |
| Genzyme Corporation | $83.92 | 2023-2025 | |
| Sobi, INC | $69.45 | 2022-2025 | |
| Tersera Therapeutics LLC | $65.48 | 2022-2023 | Zoladex, Xermelo |
| Karyopharm Therapeutics INC. | $65.13 | 2022-2023 | Xpovio |
| Rigel Pharmaceuticals, INC. | $63.78 | 2024 | Tavalisse, Rezlidhia |
| Pharmaessentia USA Corporation | $55.40 | 2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $50.43 | 2024 | Ultomiris |
| Stemline Therapeutics INC. | $49.10 | 2024-2025 | Orserdu |
| Tempus Ai, INC | $47.77 | 2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $46.67 | 2025 | |
| Beone Medicines USA, INC. | $40.66 | 2025 | Brukinsa |
| Exelixis INC. | $37.24 | 2024 | Cabometyx |
| G1 Therapeutics, INC. | $29.12 | 2022 | |
| Legend Biotech USA INC. | $27.11 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $26.08 | 2025 | Somatuline Depot, Onivyde |
| Telix Pharmaceuticals | $24.16 | 2025 | Illuccix |
| Pharmacyclics LLC, An Abbvie Company | $22.76 | 2023 | Epkinly |
| Dendreon Pharmaceuticals LLC | $21.69 | 2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $21.13 | 2024 | |
| Corcept Therapeutics | $20.75 | 2025 | Korlym |
| Pharmacosmos Therapeutics INC. | $20.01 | 2024 | Monoferric |
| Amgen INC. | $19.80 | 2023 | Xgeva |
| Secura Bio, INC. | $18.46 | 2024 | Copiktra |
| Takeda Pharmaceuticals U.S.A., INC. | $18.32 | 2024 | Iclusig |
| Array Biopharma INC | $17.23 | 2024 | Tukysa, Mektovi, Braftovi |
| Beigene USA, INC. | $17.15 | 2023 | Brukinsa |
| Mirati Therapeutics, INC. | $12.73 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Keerty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.